# Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

> **NCT04281108** · PHASE3 · COMPLETED · sponsor: **Ellodi Pharmaceuticals, LP** · enrollment: 143 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** APT-1011
- **DRUG:** Placebo oral tablet
- **PROCEDURE:** Esophagogastroduodenoscopy

## Key facts

- **NCT ID:** NCT04281108
- **Lead sponsor:** Ellodi Pharmaceuticals, LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-30
- **Primary completion:** 2022-05-05
- **Final completion:** 2022-10-24
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04281108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04281108, "Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04281108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*